Shares of Incyte (NASDAQ:INCY) were unchanged after the company reported Q4 results.
Earnings per share increased 43.08% over the past year to $0.93, which beat the estimate of $0.75.
Revenue of $789,509,000 rose by 36.27% from the same period last year, which beat the estimate of $662,940,000.
Incyte said it sees Jakafi net product sales of $2.125 billion-$2.200 billion.
How To Listen To The Conference Call
Date: Feb 09, 2021
Time: 08:00 AM
Company's 52-week high was at $110.36
52-week low: $62.48
Price action over last quarter: Up 12.59%
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). Incyte's pipeline includes a broad array of oncology and dermatology programs.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.